CRC_2014 0443

HER2 3+ Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

This will be a multi-center, prospective, randomized, single-blinded, placebo-controlled phase II trial of trastuzumab + nelipepimut-S/GM-CSF versus trastuzumab + GM-CSF alone. Our target study population is high-risk HER2-positive breast cancer patients. High-risk HER2-positive breast cancer patients are defined as: Those with HER2-positive breast cancer, regardless of hormone receptor status, who receive neoadjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy, and fail to achieve a pCR. Those with HER2-positive breast cancer, regardless of hormone receptor status, who undergo surgery as a first intervention and are found to have ≥ 4 positive lymph nodes. Those with HER2-positive, hormone receptor negative breast cancer who undergo surgery as a first intervention and are found to have 1-3 positive lymph nodes. Disease-free subjects after standard of care multi-modality therapy will be screened and HLA-typed.

Key Inclusion Criteria:
•Stage I-III
•HER2 positive
•Completed Chemo/Radiation/Surgery
•Node-positive (N2) after treatment
•N1 if ER/PR negative
•ECOG 0 – 1

Phase II
NCT02297698
Cancer, All Other
Breast
Jason Lukas, M.D., Ph.D.
Cancer Insight, LLC
Rachel Macomber
  • Providence Regional Cancer Partnership - Everett